Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings
1. COR's Q2 2025 sales increased 10.3%, missing consensus by $0.18 billion. 2. U.S. Healthcare Solutions revenue surged, driven by unit volume growth. 3. Adjusted EPS of $4.42 beat consensus, up 16.3% year over year. 4. Fiscal year 2025 guidance updated for stronger earnings growth. 5. Stock rose 4.71% to $304.505 following the report.